Then, we assessed the effects of altered UBC13 expression on paclitaxel sensitivity in A2780 and SKOV3 cells, and found that UBC13 knockdown by specific siRNA significantly protected ovarian cancer cells from paclitaxel (Fig. 3c). This evidence concerns the gene UBE2N and ovarian cancer.